92 related articles for article (PubMed ID: 7078638)
41. Myeloid cells as effector cells for monoclonal antibody therapy of cancer.
Braster R; O'Toole T; van Egmond M
Methods; 2014 Jan; 65(1):28-37. PubMed ID: 23811299
[TBL] [Abstract][Full Text] [Related]
42. Identification of feline monocytes and neutrophils as effector cells in antibody-dependent cellular cytotoxicity: sequential analysis, using light microscopy, histochemistry, and scanning electron microscopy.
Kooistra L; Splitter GA; Albrecht RM
Am J Vet Res; 1985 Dec; 46(12):2626-33. PubMed ID: 4083604
[TBL] [Abstract][Full Text] [Related]
43. Analysis of effector cells in human antibody-dependent cellular cytotoxicity with murine monoclonal antibodies.
Ortaldo JR; Woodhouse C; Morgan AC; Herberman RB; Cheresh DA; Reisfeld R
J Immunol; 1987 May; 138(10):3566-72. PubMed ID: 2437198
[TBL] [Abstract][Full Text] [Related]
44. Further characterization of cooperative interactions of monoclonal antibodies.
Ehrlich PH; Moyle WR; Moustafa ZA
J Immunol; 1983 Oct; 131(4):1906-12. PubMed ID: 6619545
[TBL] [Abstract][Full Text] [Related]
45. Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities.
Gillies SD; Wesolowski JS
Hum Antibodies Hybridomas; 1990; 1(1):47-54. PubMed ID: 2129419
[TBL] [Abstract][Full Text] [Related]
46. Antibody-dependent cell-mediated cytolysis of human colon carcinoma cells induced by specific antisera against carcinoembryonic antigen.
Carrel S; Delisle MC; Mach JP
Cancer Res; 1977 Aug; 37(8 Pt 1):2644-50. PubMed ID: 872092
[TBL] [Abstract][Full Text] [Related]
47. [Anti-tumor effects of the anti-hCG antibody on choriocarcinoma].
Tadera S; Yamanaka N; Okada Y; Kamidono S; Ishigami J; Nishimura R; Mochizuki M
Nihon Gan Chiryo Gakkai Shi; 1985 Apr; 20(3):550-5. PubMed ID: 4056541
[No Abstract] [Full Text] [Related]
48. [Specific effects of methotrexate bound to the antibodies against hCG and placental alkaline phosphatase to the cultured human choriocarcinoma cells].
Hattori S; Furuhashi Y; Goto S; Tomoda Y
Nihon Sanka Fujinka Gakkai Zasshi; 1983 Jan; 35(1):33-40. PubMed ID: 6681830
[TBL] [Abstract][Full Text] [Related]
49. Demonstration of cell-mediated and humoral antibodies in patients with malignant breast and ovary-tumours.
Kitschke HJ; Krebs D
Acta Eur Fertil; 1973 Jun; 4(2):75-7. PubMed ID: 4784141
[No Abstract] [Full Text] [Related]
50. Human cytotoxic response in vitro to trinitrophenyl-modified autologous cells. I. T cell recognition of TNP in association with widely shared antigens.
Shaw S; Nelson DL; Shearer GM
J Immunol; 1978 Jul; 121(1):281-9. PubMed ID: 78943
[No Abstract] [Full Text] [Related]
51. Separation of cell-dependent antibody (CDA) and inhibitory antibody by protein-A affinity chromatography and the effect of fractions on antibody-dependent cellular cytotoxicity (ADCC).
Sato N; Yabuki Y; Toh K; Ishii Y; Kikuchi K
Immunology; 1979 Mar; 36(3):421-6. PubMed ID: 437836
[TBL] [Abstract][Full Text] [Related]
52. Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2.
Golay J; Manganini M; Facchinetti V; Gramigna R; Broady R; Borleri G; Rambaldi A; Introna M
Haematologica; 2003 Sep; 88(9):1002-12. PubMed ID: 12969808
[TBL] [Abstract][Full Text] [Related]
53. Blocking of syngeneic effector T cells by soluble tumour antigens.
Plata F; Levy JP
Nature; 1974 May; 249(454):271-4. PubMed ID: 4545403
[No Abstract] [Full Text] [Related]
54. Functions of the various IgG Fc receptors in mediating killing of Toxoplasma gondii.
Erbe DV; Pfefferkorn ER; Fanger MW
J Immunol; 1991 May; 146(9):3145-51. PubMed ID: 1826707
[TBL] [Abstract][Full Text] [Related]
55. Inhibition of specific cell-mediated cytotoxicity by monoclonal antibodies to human T cell antigens.
Platsoucas CD; Good RA
Proc Natl Acad Sci U S A; 1981 Jul; 78(7):4500-4. PubMed ID: 6974866
[TBL] [Abstract][Full Text] [Related]
56. The production and preclinical characterization of a chimeric anti-breast-cancer antibody, cBC2.
Sutton VR; Burgess J; Pietersz GA; Li WJ; McKenzie IF; Trapani JA
Ther Immunol; 1994 Apr; 1(2):83-93. PubMed ID: 7584487
[TBL] [Abstract][Full Text] [Related]
57. Specific blocking factors--are they important?
Hellström KE; Hellström I; Nepom JT
Biochim Biophys Acta; 1977 Dec; 473(2):121-48. PubMed ID: 73383
[No Abstract] [Full Text] [Related]
58. Role of immunity in therapy of human cancer. Discussion.
Br J Cancer Suppl; 1973 Aug; 1():299-308. PubMed ID: 4804287
[No Abstract] [Full Text] [Related]
59. Induction of immune cytolysis: tumor-cell killing by complement is initiated by covalent complex of monoclonal antibody and stable C3/C5 convertase.
Vogel CW; Müller-Eberhard HJ
Proc Natl Acad Sci U S A; 1981 Dec; 78(12):7707-11. PubMed ID: 6950410
[TBL] [Abstract][Full Text] [Related]
60. Bispecific molecules directed to the Fc receptor for IgA (Fc alpha RI, CD89) and tumor antigens efficiently promote cell-mediated cytotoxicity of tumor targets in whole blood.
Deo YM; Sundarapandiyan K; Keler T; Wallace PK; Graziano RF
J Immunol; 1998 Feb; 160(4):1677-86. PubMed ID: 9469424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
